Literature DB >> 25684993

Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer.

F Santos1, A Dragomir2, W Kassouf2, E Franco1, A Aprikian2.   

Abstract

BACKGROUND: Evidence shows that wait times before bladder cancer surgery have been increasing, and wait time can negatively affect survival. We aimed to determine if a long delay caused by an indirect referral before a first urologist visit affects the survival of patients undergoing radical cystectomy for bladder cancer.
METHODS: We analyzed data from 1271 patients who underwent surgery for bladder cancer during the decade 2000-2009. The cohort was obtained by linking two administrative databases in the province of Quebec. Patients were considered to have been directly referred to a urologist if they had 5 or fewer visits with a general practitioner before their first urologist visit; otherwise, they were considered to have been indirectly referred. The effect on survival after surgery of a longer delay before a first urologist visit was assessed using Cox regression models.
RESULTS: Median referral delay for the study population was 30 days (56 days for women, 23 days for men; p < 0.0001). Indirect referral was observed for 49% of women and 33% of men. Compared with patients who were directly referred, those who were indirectly referred after first symptoms of bladder cancer experienced poorer survival (hazard ratio: 1.29; 95% confidence interval: 1.10 to 1.52). Women who were indirectly referred had a significant 47% greater risk of death after radical cystectomy. Men who were indirectly referred also experienced decreased survival (adjusted hazard ratio: 1.25; 95% confidence interval: 1.03 to 1.51).
CONCLUSIONS: Patients indirectly referred to a urologist had an increased risk of mortality after surgery. Compared with men, women had longer wait times and poorer survival.

Entities:  

Keywords:  Urologist referral delay; bladder cancer; cohort study; radical cystectomy; survival

Year:  2015        PMID: 25684993      PMCID: PMC4324349          DOI: 10.3747/co.22.2052

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  19 in total

1.  Examining the association between delay in diagnosis and decreased survival in bladder cancer.

Authors:  Michael P Porter
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

Review 2.  Female bladder cancer: incidence, treatment, and outcome.

Authors:  Emil Scosyrev; Deep Trivedi; Edward Messing
Journal:  Curr Opin Urol       Date:  2010-09       Impact factor: 2.309

3.  Long-term outcome of hematuria home screening for bladder cancer in men.

Authors:  Edward M Messing; Ralph Madeb; Terry Young; Kennedy W Gilchrist; Lora Bram; E Barry Greenberg; John D Wegenke; Laura Stephenson; Jason Gee; Changyong Feng
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

4.  Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system.

Authors:  Faysal A Yafi; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

5.  Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer?

Authors:  Armin Henning; Marlies Wehrberger; Stephan Madersbacher; Armin Pycha; Thomas Martini; Evi Comploj; Klaus Jeschke; Christian Tripolt; Michael Rauchenwald
Journal:  BJU Int       Date:  2013-01-15       Impact factor: 5.588

6.  Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey.

Authors:  Alan M Nieder; Yair Lotan; Geoffrey R Nuss; Joshua P Langston; Sachin Vyas; Murugesan Manoharan; Mark S Soloway
Journal:  Urol Oncol       Date:  2008-12-20       Impact factor: 3.498

7.  Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.

Authors:  M May; T Nitzke; C Helke; H Vogler; B Hoschke
Journal:  Scand J Urol Nephrol       Date:  2004

8.  Patterns of hematuria referral to urologists: does a gender disparity exist?

Authors:  Emilie K Johnson; Stephanie Daignault; Yingxi Zhang; Cheryl T Lee
Journal:  Urology       Date:  2008-07-10       Impact factor: 2.649

9.  An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec.

Authors:  Nader Fahmy; Wassim Kassouf; Suganthiny Jeyaganth; Moamen Amin; Salaheddin Mahmud; Jordan Steinberg; Simon Tanguay; Armen Aprikian
Journal:  Can Urol Assoc J       Date:  2008-04       Impact factor: 1.862

Review 10.  The effect of age and gender on bladder cancer: a critical review of the literature.

Authors:  Shahrokh F Shariat; John P Sfakianos; Michael J Droller; Pierre I Karakiewicz; Siegfried Meryn; Bernard H Bochner
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588

View more
  9 in total

1.  Raising the bar for bladder cancer care.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

2.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

Review 3.  Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.

Authors:  Di Maria Jiang; Shilpa Gupta; Abhijat Kitchlu; Alejandro Meraz-Munoz; Scott A North; Nimira S Alimohamed; Normand Blais; Srikala S Sridhar
Journal:  Nat Rev Urol       Date:  2021-01-11       Impact factor: 14.432

4.  Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival.

Authors:  Joanne Watt; Daniel G Maguire; Cherith N Reid; John V Lamont; Stephen P Fitzgerald; Mark W Ruddock
Journal:  Res Rep Urol       Date:  2020-04-28

5.  Projected US Urology Workforce per Capita, 2020-2060.

Authors:  Catherine S Nam; Stephanie Daignault-Newton; Kate H Kraft; Lindsey A Herrel
Journal:  JAMA Netw Open       Date:  2021-11-01

Review 6.  A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond.

Authors:  Jeffrey J Leow; Wei Shen Tan; Wei Phin Tan; Teck Wei Tan; Vinson Wai-Shun Chan; Kari A O Tikkinen; Ashish Kamat; Shomik Sengupta; Maxwell V Meng; Shahrokh Shariat; Morgan Roupret; Karel Decaestecker; Nikhil Vasdev; Yew Lam Chong; Dmitry Enikeev; Gianluca Giannarini; Vincenzo Ficarra; Jeremy Yuen-Chun Teoh
Journal:  Front Surg       Date:  2022-10-04

7.  Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy.

Authors:  Renate Pichler; Josef Fritz; Isabel Heidegger; Wilhelm Oberaigner; Wolfgang Horninger; Margarethe Hochleitner
Journal:  J Cancer       Date:  2017-09-30       Impact factor: 4.207

8.  Quality of the diagnostic process in patients presenting with symptoms suggestive of bladder or kidney cancer: a systematic review.

Authors:  Yin Zhou; Marije van Melle; Hardeep Singh; Willie Hamilton; Georgios Lyratzopoulos; Fiona M Walter
Journal:  BMJ Open       Date:  2019-10-03       Impact factor: 2.692

9.  Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma.

Authors:  M Brugel; O Bouché; R Kianmanesh; L Teuma; A Tashkandi; J M Regimbeau; P Pessaux; B Royer; R Rhaiem; C Perrenot; C Neuzillet; T Piardi; S Deguelte
Journal:  BMC Surg       Date:  2021-12-07       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.